PTC Therapeutics Q3 total revenues $196.6M (-9% YoY), net loss $133M; updates pipeline timelines

PTC THERAPEUTICS, INC.

2023-Q3 EPS reported -$6.31 revenue$630,766,000

DMD franchise revenue $136M in Q3; full-year 2023 DMD guidance raised to $565-595M.
Translarna net revenue $69M; CHMP re-examination expected Jan 2024; FDA type C meeting in Q4 2023.
Sepiapterin NDA submission for PKU delayed to no later than Q3 2024; MAA to EMA in H1 2024.
PTC518 HD trial enrollment ongoing; FDA requires 6-month safety data for US dosing.
Total 2023 revenue guidance $940M-$1.0B; GAAP R&D+SG&A expenses $915-965M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PTC THERAPEUTICS, INC. reported the third quarter ending September 30, 2023 results: revenue $196.6 million. Guidance reaffirmed.

Period: the third quarter ending September 30, 2023
Revenue: $196.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues were $196.6 million for the third quarter of 2023, compared to $217.1 million for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.